# Untangling obese asthma: Design of proof-of-concept study of semaglutide in poorly controlled asthma

## TL;DR

This paper introduces a new clinical trial design to better understand and treat asthma in obese patients by considering metabolic factors beyond body mass index.

## Contribution

The study proposes a novel trial framework integrating metabolic profiling into asthma research to address obesity-related disease complexity.

## Key findings

- Current asthma research often oversimplifies the obesity-asthma relationship by focusing only on BMI.
- The GATA-3 trial is the first placebo-controlled study to evaluate the GLP-1R pathway in asthma independent of weight loss.
- Integrating metabolic assessments can improve treatment strategies for obese asthma patients.

## Abstract

The intersection of obesity and asthma represents a complex clinical challenge characterized by increased symptom burden, reduced treatment efficacy, and multifactorial pathophysiology. Obesity-associated asthma is a heterogeneous condition shaped by underlying metabolic dysfunctions such as insulin resistance and altered inflammatory processes.

Current research often oversimplifies the relationship between obesity and asthma by relying primarily on body mass index as a measure, thereby overlooking key metabolic factors that may influence disease severity and treatment response. There is a critical need for clinical trials that account for this metabolic complexity, so we designed a proof-of-concept study with this in mind.

Using the GLP-1R Agonists in the Treatment of Adult, Symptomatic, Obese Asthma (GATA-3) trial (ClinicalTrials.gov NCT05254314) as a conceptual framework, we propose an evolved model for future asthma research. While not a direct report of GATA-3 findings, it emphasizes the integration of comprehensive metabolic profiling—including insulin sensitivity and body composition—alongside traditional inflammatory and respiratory metrics in randomized controlled asthma trials.

The GATA-3 study design serves as an example of the first placebo-controlled trial to evaluate the glucagon-like peptide 1 receptor pathway’s role in asthma management independent of weight loss. The trial underscores essential design elements such as accurate asthma diagnosis, recognition of endotype heterogeneity, and implementation of outcome measures tailored to this phenotype.

Advancing our understanding of obesity-associated asthma requires moving beyond body mass index–focused models to fully consider the metabolic complexity of the disease. Integrating detailed metabolic assessments into research and clinical practice will be vital for identifying responsive subpopulations, optimizing treatment strategies, and ultimately improving patient outcomes.